Autologous cell therapy - PolarityBio
Alternative Names: SkinTE®Latest Information Update: 16 Sep 2025
At a glance
- Originator PolarityTE
- Developer PolarityBio
- Class Cell therapies
- Mechanism of Action Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Diabetic foot ulcer
- Clinical Phase Unknown Leg ulcer
- Preclinical Burns; Wounds
Most Recent Events
- 16 Sep 2025 Autologous cell therapy is still in clinical trials for Leg ulcer (Adjunctive treatment) in USA (PolarityTE pipeline, September 2025)
- 02 Sep 2025 PolarityBio received US FDA clearance for expanded access treatment protocol for Diabetic foot ulcer
- 02 Sep 2025 PolarityBio plans a expanded access programme for Diabetic foot ulcer